Erasca arrives at its May 15 earnings event trading near the bottom of a sharp pullback — down 39% over the past month to $10.44 — yet short sellers are pressing harder and the options market has pivoted from bullish to defensive.
Short interest tells an aggressive story heading into the print. At 12.2% of the free float, it has climbed more than 27% over the past month — a meaningful acceleration that began around late April. That buildup largely reflects new positioning rather than a squeeze: borrow remains exceptionally cheap at just 0.49%, and availability is wide, indicating the lending pool is far from exhausted. Bears have found this an easy stock to get short.
Options positioning has shifted sharply in the same direction. The put/call ratio is running at 0.34, well above its 20-day average of 0.28 — and notable because just six weeks ago the PCR was below 0.12, near the 52-week floor of 0.002. The rotation from near-pure call dominance to meaningfully higher put volume tracks almost exactly with the stock's slide from the mid-$20s. Investors who were positioned aggressively bullish into the March catalyst have recalibrated toward protection.
The bull case rests on pipeline quality. Erasca's two lead assets — ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor — target the RAS/MAPK pathway, a well-validated but hard-to-drug mechanism in oncology. Analyst consensus remains solidly bullish: Stifel lifted its target from $20 to $30 on April 27, and JPMorgan raised to $25 in March — both maintaining positive ratings even after the stock's steep decline. The mean target now implies more than 100% upside from current levels, though the Street's confidence sits in the clinical data rather than near-term revenues given the company carries negative earnings multiples. Bears counter that proof of concept for deep pathway suppression is still unproven and that early monotherapy results must demonstrate responses across multiple KRAS alleles to justify premium positioning.
Historical reactions add another layer of uncertainty. The last three earnings-related events have delivered pronounced moves: a 12% single-day drop in March, a 6% fall in November, and a 7.6% gain in between. The May 15 print tests whether the 39% selloff since mid-April has already discounted a disappointing clinical update — or whether investors are right to keep reaching for downside protection.
See the live data behind this article on ORTEX.
Open ERAS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
